Video

Dr. Westin on Challenges With Precision Medicine in Endometrial Cancer

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer. 

Shannon N. Westin, MD, MPH, clinical investigator and director of Early Drug Development and Phase I Trials in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, discusses challenges with precision medicine in endometrial cancer. 

Despite encouraging data ​with combination ​regimens such as lenvatinib (Lenvima) and pembrolizumab (Keytruda), ​toxicity remains a challenge, says Westin.

​However, this does not mean that chemotherapy is the better alternative, ​she adds.

Precision medicine shows promise in the endometrial cancer space ​and research efforts are aimed at developing strategies to mitigate or prevent treatment-related adverse effects (AEs), ​Westin says.

Often, patients​ who experience AEs may want to stop treatment, even if the regimen is working. Finding a way to mitigate AEs will help patients remain on effective therapies, Westin concludes. 

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity